Type 1 Diabetes Mellitus
Conditions
Keywords
Type 1 diabetes mellitus, Diabetic retinopathy, Pathogenesis, Dynamic Vessel Analyser, Endothelial dysfunction
Brief summary
The aim of the study is to progress in the understanding of the early retinal vascular and neural abnormalities in patients with diabetes, using a new device, the Dynamic Vessel Analyzer. The Dynamic Vessel Analyzer allows to measure the diameter of the retinal vessels and to assess how it varies in presence of various stimuli. Then, we will be able to assess if a vascular and/or a neural dysfunction is present early in patient with diabetes.
Detailed description
Twenty patients with type 1 diabetes without diabetic retinopathy and without arterial hypertension will be compared with 20 sex and aged-matched healthy control subjects. To assess the presence of retinal endothelial dysfunction, the variations of the diameters of the retinal vessels will be assessed using the Dynamic Vessel Analyzer, before and after flicker light stimulation, sublingual nitroglycerin, neosynephrine eyedrops, and isometric contraction. To assess the presence of peripheral endothelial dysfunction, the microcirculation of the forearm skin will be studied using iontophoresis with acetylcholine delivery, and heat delivery, both coupled with blood flow measurement using laser Doppler. An intravital capillaroscopy of the phalanx skin will be performed. The serum levels of CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin will also be measured.
Interventions
DRUGTrinitrin
Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
DRUGNeosynephrine 10% collyrium
Neosynephrine 10% collyrium: 2 drops
DRUGIontophoresis with acetylcholine delivery
Iontophoresis with acetylcholine delivery
DEVICEDynamic Vessel Analyzer
Dynamic Vessel Analyzer
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* For diabetic patients : * age between 20 and 60 * type 1 diabetes mellitus * diabetes duration of more than 5 years * no diabetic retinopathy on fundus examination or fundus photographs * no systemic hypertension (defined as systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg) * For control subjects : * sex and age matching with the diabetic patients * no diabetes, no familial or personal history of elevated blood sugar * Non-diabetic subjects, criteria defined by a fasting glucose \<1.10 g / l and an HbA1c \<6.5% (according to Lariboisière biochemistry laboratory HbA1c) * no systemic hypertension (defined as systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg) * Subject with a normal ophthalmologic examination * For both diabetic patients and control subjects : * Subject that has signed informed consent * Subject affiliated to a social security * Subject available for a period of 4 months
Exclusion criteria
* For both diabetic patients and control subjects : * presence of cataract or history of cataract surgery * intraocular pressure of more than 21 mmHg * treatment with vasoactive drugs * tobacco consumption of more than 20 cigarettes a day * Contraindications to trinitrin administration: hypersensitivity to trinitrin, treatment by sildenafil, heart disease, severe arterial hypotension, bradycardia, intracranial hypertension * Clinical Raynaud syndrome * Pregnant or breast-feeding subject * Subject whose age is \<18 and\> 60 years on the day of inclusion * Subject with cardiac disease, severe hypotension (BP \<80/50 mmHg), a resting heart rate below 50 beats / minute * Subject intracranial hypertension * Subject with a current consumption of drugs or drugs that may impact vasomotion (antiglaucoma eye drops, vasodilators, antihypertensive drugs). Vasoactive drug use will be prohibited within 24 hours preceding the study. * Subject has not signed an informed consent * Subject not affiliated to a social security * Subject not available for a period of 4 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit) | up to 4 months |
Secondary
| Measure | Time frame |
|---|---|
| Presence of a peripheral endothelial dysfunction | up to 4 months |
| Correlation between retinal and peripheral endothelial dysfunction (assessment study visit) | up to 4 months |
| Serum concentration of: CRP, ICAM-1, VCAM-1, VEGF, angiopoietin 2 and endostatin. | up to 4 months |
Countries
France
Outcome results
None listed